Currently out of the existing stock ratings of Keyur Parekh, 4 are a HOLD (33.33%), 8 are a BUY (66.67%).

Keyur Parekh

Work Performance Price Targets & Ratings Chart

Analyst Keyur Parekh, carries an average stock price target met ratio of 60% that have a potential upside of 39.78% achieved within 734 days. Previously, Keyur Parekh worked at GOLDMAN SACHS.

Keyur Parekh’s has documented 20 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 24-Feb-2023.

Wall Street Analyst Keyur Parekh

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 1/26/2022. The price target of $60.58 was fulfilled within 322 days with a profit of $19.07 (45.94%) receiving and performance score of 1.43.

Average potential price target upside

AZN AstraZeneca PLC ADR NVS Novartis AG ADR SNY Sanofi ADR NVO Novo Nordisk A/S GSK GlaxoSmithKline PLC ADR DBVT DBV Technologies ZEAL Zealand Pharma A/S ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Dec-2019

$240

$68.51 (39.95%)

$105

6 months 25 days ago
(30-Mar-2026)

12/15 (80%)

$47.4 (24.61%)

572

Buy Since 27-Jan-2020

$220

$48.51 (28.29%)

$174

6 months 28 days ago
(27-Mar-2026)

5/16 (31.25%)

$32.82 (17.53%)

570

Buy Since 11-Apr-2023

$109

$-62.49 (-36.44%)

$168

7 months 23 days ago
(02-Mar-2026)

1/3 (33.33%)

$-93.39 (-46.14%)

128

Buy Since 05-Sep-2023

$108.5

$-79.91 (-42.41%)

$91.7

11 months ago
(25-Nov-2025)

1/6 (16.67%)

$-76.04 (-41.21%)

483

Hold Since 27-Oct-2025

11 months 28 days ago
(27-Oct-2025)

2/3 (66.67%)

$-6.12 (-4.81%)

958

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?